Miyamoto Shunsuke, Hatayama Tomoya, Shikuma Hiroyuki, Yukihiro Kazuma, Iwane Kyohsuke, Tasaka Ryo, Kohada Yuki, Fukushima Takafumi, Takemoto Kenshiro, Naito Miki, Kobatake Kohei, Sekino Yohei, Kitano Hiroyuki, Ikeda Kenichiro, Goto Keisuke, Goriki Akihiro, Hieda Keisuke, Hinata Nobuyuki
Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Asian J Urol. 2025 Apr;12(2):162-168. doi: 10.1016/j.ajur.2024.05.002. Epub 2024 Aug 24.
To assess the safety and effectiveness of urological tumor surgeries using the hinotori™ Surgical Robot System (hinotori) in a real-world clinical setting.
All surgeries including robot-assisted radical prostatectomy (RARP), robot-assisted partial nephrectomy (RAPN), robot-assisted radical nephrectomy (RARN), robot-assisted nephroureterectomy (RANU), robot-assisted adrenalectomy (RAA), and robot-assisted radical cystectomy with intracorporeal urinary diversion (RARC+ICUD) for urological tumors with the hinotori and da Vinci surgical system (da Vinci) from January 2022 to September 2023 were enrolled. We evaluated the safety and effectiveness of surgeries using the hinotori compared with those using the da Vinci.
Robotic surgeries using the hinotori were performed in a total of 91 cases, comprising 42 cases of RARP, 18 cases of RAPN, six cases of RARN, 10 cases of RANU, 13 cases of RAA, and two cases of RARC+ICUD; no major intraoperative complications were observed in any of the cases using the hinotori; no major postoperative complications occurred in any of the cases; no case experienced an unrecoverable equipment error during surgery. Meanwhile, robotic surgeries using the da Vinci were performed in a total of 277 cases, comprising 126 cases of RARP, 94 cases of RAPN, 12 cases of RARN, 10 cases of RANU, 20 cases of RAA, and 15 cases of RARC+ICUD; major intraoperative complications occurred in two cases; major postoperative complications occurred in seven cases; seven cases required transfusion; one case underwent conversion to open surgery; during the study period, no case experienced an unrecoverable equipment error. Surgical outcomes for cases with the hinotori were comparable to those with the da Vinci.
This study demonstrated that the hinotori is a safe and feasible tool for robotic surgeries in the field of urology.
在真实临床环境中评估使用火鸟™手术机器人系统（火鸟）进行泌尿外科肿瘤手术的安全性和有效性。
纳入2022年1月至2023年9月期间使用火鸟和达芬奇手术系统（达芬奇）进行的所有泌尿外科肿瘤手术，包括机器人辅助根治性前列腺切除术（RARP）、机器人辅助部分肾切除术（RAPN）、机器人辅助根治性肾切除术（RARN）、机器人辅助肾输尿管切除术（RANU）、机器人辅助肾上腺切除术（RAA）以及机器人辅助根治性膀胱切除术加体内尿流改道术（RARC+ICUD）。我们比较了使用火鸟与使用达芬奇进行手术的安全性和有效性。
使用火鸟进行的机器人手术共91例，包括42例RARP、18例RAPN、6例RARN、10例RANU、13例RAA和2例RARC+ICUD；使用火鸟的任何病例均未观察到重大术中并发症；任何病例均未发生重大术后并发症；手术期间无病例出现不可恢复的设备故障。同时，使用达芬奇进行的机器人手术共277例，包括126例RARP、94例RAPN、12例RARN、10例RANU、20例RAA和15例RARC+ICUD；2例发生重大术中并发症；7例发生重大术后并发症；7例需要输血；1例转为开放手术；在研究期间，无病例出现不可恢复的设备故障。火鸟组病例的手术结果与达芬奇组相当。
本研究表明，火鸟是泌尿外科领域机器人手术的一种安全可行的工具。
